- Home
- WLYB vs IDYA Comparison
WLYB vs IDYA Comparison
Compare WLYB & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- IDYA
- Stock Information
- Founded
- WLYB 1807
- IDYA 2015
- Country
- WLYB United States
- IDYA United States
- Employees
- WLYB N/A
- IDYA N/A
- Industry
- WLYB Books
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- WLYB Consumer Discretionary
- IDYA Health Care
- Exchange
- WLYB Nasdaq
- IDYA Nasdaq
- Market Cap
- WLYB 2.4B
- IDYA 2.2B
- IPO Year
- WLYB N/A
- IDYA 2019
- Fundamental
- Price
- WLYB $43.70
- IDYA $22.18
- Analyst Decision
- WLYB
- IDYA Strong Buy
- Analyst Count
- WLYB 0
- IDYA 13
- Target Price
- WLYB N/A
- IDYA $53.67
- AVG Volume (30 Days)
- WLYB 255.0
- IDYA 890.0K
- Earning Date
- WLYB 03-06-2025
- IDYA 02-18-2025
- Dividend Yield
- WLYB 3.22%
- IDYA N/A
- EPS Growth
- WLYB N/A
- IDYA N/A
- EPS
- WLYB N/A
- IDYA N/A
- Revenue
- WLYB $1,759,570,000.00
- IDYA $3,922,000.00
- Revenue This Year
- WLYB N/A
- IDYA N/A
- Revenue Next Year
- WLYB $1.13
- IDYA $251.89
- P/E Ratio
- WLYB N/A
- IDYA N/A
- Revenue Growth
- WLYB N/A
- IDYA N/A
- 52 Week Low
- WLYB $32.60
- IDYA $22.10
- 52 Week High
- WLYB $52.90
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- WLYB 43.40
- IDYA 31.90
- Support Level
- WLYB $41.61
- IDYA $22.17
- Resistance Level
- WLYB $52.29
- IDYA $24.06
- Average True Range (ATR)
- WLYB 0.10
- IDYA 1.06
- MACD
- WLYB 0.28
- IDYA -0.22
- Stochastic Oscillator
- WLYB 85.31
- IDYA 1.84
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is a provider of academic journals, books, pre- and post-hire assessments and training, test preparation materials, and online education program management solutions. The company's reportable segments are; Research, Learning, Held for Sale or Sold. The majority of the company's revenue is generated from the Research segment which provides peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. Geographically, it derives maximum revenue from the United States and the rest from the United Kingdom, China, Japan, Canada, and other countries.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.